89bio [ETNB] vs Moderna [MRNA] Detailed Stock Comparison
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: 89bio Inc. wins in 9 metrics, Moderna Inc. wins in 7 metrics, with 0 ties. 89bio Inc. appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | 89bio Inc. | Moderna Inc. | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -4.23 | 24.97 | Moderna Inc. |
| Price-to-Book Ratio | 4.22 | 2.47 | Moderna Inc. |
| Debt-to-Equity Ratio | 7.21 | 15.09 | 89bio Inc. |
| PEG Ratio | -0.09 | -0.91 | 89bio Inc. |
| EV/EBITDA | -3.60 | -5.92 | 89bio Inc. |
| Profit Margin (TTM) | 0.00% | -145.16% | 89bio Inc. |
| Operating Margin (TTM) | 0.00% | -126.40% | 89bio Inc. |
| Return on Equity | -86.86% | -28.87% | Moderna Inc. |
| Return on Assets (TTM) | -49.10% | -14.51% | Moderna Inc. |
| Free Cash Flow (TTM) | $-367.84M | $-2.08B | 89bio Inc. |
| 1-Year Return | 62.36% | 77.67% | Moderna Inc. |
| Price-to-Sales Ratio (TTM) | N/A | 11.06 | N/A |
| Enterprise Value | $1.68B | $16.92B | Moderna Inc. |
| EV/Revenue Ratio | N/A | 8.71 | N/A |
| Gross Profit Margin (TTM) | N/A | 33.14% | N/A |
| Revenue per Share (TTM) | $0 | $5 | Moderna Inc. |
| Earnings per Share (Diluted) | $-3.69 | $-7.26 | 89bio Inc. |
| Beta (Stock Volatility) | 1.26 | 1.34 | 89bio Inc. |
| Short % of Float | 6.30% | 18.71% | 89bio Inc. |
89bio Inc. vs Moderna Inc. Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| 89bio Inc. | 0.00% | 0.27% | 0.95% | 55.72% | 85.04% | 170.31% |
| Moderna Inc. | 7.49% | 3.05% | 3.72% | -1.55% | 94.84% | 58.98% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| 89bio Inc. | 62.36% | 69.60% | -39.87% | -28.65% | -28.65% | -28.65% |
| Moderna Inc. | 77.67% | -63.84% | -77.10% | 153.71% | 153.71% | 153.71% |
Performance & Financial Health Analysis: 89bio Inc. vs Moderna Inc.
| Metric | ETNB | MRNA |
|---|---|---|
| Market Information | ||
| Market Cap | $2.20B | $20.96B |
| Market Cap Category | Mid cap | Large cap |
| 10 Day Avg. Volume | 8,673,209 | 6,250,502 |
| 90 Day Avg. Volume | 7,032,596 | 6,358,614 |
| Last Close | $14.84 | $49.06 |
| 52 Week Range | $4.16 - $15.06 | $22.28 - $59.55 |
| % from 52W High | -1.46% | -17.62% |
| All-Time High | $47.25 (Mar 02, 2020) | $497.49 (Aug 09, 2021) |
| % from All-Time High | -68.59% | -90.14% |
| Growth Metrics | ||
| Quarterly Revenue Growth | N/A | -0.30% |
| Quarterly Earnings Growth | N/A | -0.29% |
| Financial Health | ||
| Profit Margin (TTM) | 0.00% | -1.45% |
| Operating Margin (TTM) | 0.00% | -1.26% |
| Return on Equity (TTM) | -0.87% | -0.29% |
| Debt to Equity (MRQ) | 7.21 | 15.09 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $3.52 | $21.95 |
| Cash per Share (MRQ) | $3.78 | $14.68 |
| Operating Cash Flow (TTM) | $-439,100,992 | $-1,872,999,936 |
| Levered Free Cash Flow (TTM) | $-257,733,632 | $-1,326,499,968 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: 89bio Inc. vs Moderna Inc.
| Metric | ETNB (Nov 19, 2025) | MRNA (Apr 24, 2026) |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -4.23 | 24.97 |
| Forward P/E | -5.17 | -11.75 |
| PEG Ratio | -0.09 | -0.91 |
| Price to Sales (TTM) | N/A | 11.06 |
| Price to Book (MRQ) | 4.22 | 2.47 |
| Market Capitalization | ||
| Market Capitalization | $2.20B | $20.96B |
| Enterprise Value | $1.68B | $16.92B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | N/A | 8.71 |
| Enterprise to EBITDA | -3.60 | -5.92 |
| Risk & Other Metrics | ||
| Beta | 1.26 | 1.34 |
| Book Value per Share (MRQ) | $3.52 | $21.95 |
Financial Statements Comparison: 89bio Inc. vs Moderna Inc.
Financial Metrics
Loading Financial Charts...
Revenue
Operating Margin
Profit Margin
Long Term Debt
Income Flow Analysis
Financial Statements Comparison
Income Statement
| Metric | ETNB (2024) | MRNA (2025) |
|---|---|---|
| Revenue/Sales | 0 | 1.92B |
| Cost of Goods Sold | N/A | 868.00M |
| COGS % of Revenue | - | 45.2% |
| Gross Profit | N/A | 1.05B |
| Gross Margin | - | 54.8% |
| Research & Development | 345.04M | 3.13B |
| Operating Income (EBIT) | -384.66M | -3.07B |
| Operating Margin | - | -159.9% |
| EBITDA | -361.06M | -2.54B |
| EBITDA Margin | - | -132.0% |
| Pre-Tax Income | -366.39M | -2.77B |
| Pre-Tax Income % of Revenue | - | -144.0% |
| Income Tax | 692,000 | 54.00M |
| Income Tax % of Revenue | - | 2.8% |
| Net Income (Profit) | -367.08M | -2.82B |
| Profit Margin | - | -146.8% |
Balance Sheet & Liquidity Metrics
| Metric | ETNB (2024) | MRNA (2025) |
|---|---|---|
| Cash & Equivalents | 126.06M | 2.60B |
| Total Current Assets | 476.45M | 6.54B |
| Total Current Assets % of Revenue | - | 340.5% |
| Total Current Liabilities | 36.13M | 1.99B |
| Total Current Liabilities % of Revenue | - | 103.4% |
| Long-Term Debt | 36.82M | 1.26B |
| Long-Term Debt % of Revenue | - | 65.7% |
| Total Shareholders Equity | 400.79M | 8.65B |
| Retained Earnings | -824.51M | 7.22B |
| Retained Earnings % of Revenue | - | 375.8% |
| Property, Plant & Equipment | 23,000 | 1.39B |
Cash Flow Statement Comparison
| Metric | ETNB (2024) | MRNA (2025) |
|---|---|---|
| Operating Cash Flow | -337.58M | -1.97B |
| Operating Cash Flow % of Revenue | - | -102.2% |
| Capital Expenditures | -15,000 | -192.00M |
| Free Cash Flow | -367.84M | -2.08B |
| FCF Margin | - | -108.0% |
| Debt Repayment | 0 | -22.00M |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | ETNB | MRNA |
|---|---|---|
| Shares Short | 6.77M | 60.65M |
| Short Ratio | 0.74 | 7.11 |
| Short % of Float | 6.30% | 18.71% |
| Shares Outstanding | 148.30M | 394.00M |
| Float Shares | 97.04M | 368.43M |
| % Held by Insiders | 0.60% | 7.32% |
| % Held by Institutions | 103.69% | 77.05% |
| % Held by Public | -4.29% | 15.63% |
Dividend Analysis & Yield Comparison: 89bio Inc. vs Moderna Inc.
| Metric | ETNB | MRNA |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |